财务数据和关键指标变化 - 公司截至2023年9月30日的现金余额为1.22亿欧元,有望为公司运营提供资金支持至2025年下半年 [95] 各条业务线数据和关键指标变化 - 公司正在推进其最先进的自有药物候选物lacutamab的临床开发,包括在T细胞淋巴瘤适应症(Sézary综合征和菌状肉芽肿)以及外周T细胞淋巴瘤的临床试验 [21][22] - 公司的NK细胞募集平台ANKET正在取得进展,其中Sanofi已经授权了3个ANKET分子,其中2个正在临床试验,公司自身的ANKET候选物IPH65也已获得IND批准并即将进入临床 [32][33][34][35][40][41] - 公司的抗体偶联药物(ADC)管线也在发展,其中针对Nectin-4靶点的ADC候选物IPH45展现出良好的临床前数据,有望于明年提交IND申请 [43][44][45][46] 各个市场数据和关键指标变化 - 无相关内容 公司战略和发展方向及行业竞争 - 公司的业务模式围绕三大支柱:推进自有管线、利用抗体工程能力开发创新分子、建立广泛的合作伙伴关系 [10][11][12][14][16] - 公司正在推进lacutamab的快速上市策略,并计划通过合作伙伴来推进后续的临床开发和商业化 [11][12][66] - 公司正在不断丰富ANKET和ADC管线,为长期发展奠定基础 [14][15][32][43] - 公司与阿斯利康、赛诺菲等公司的合作伙伴关系在推进中 [16][40][41] 管理层对经营环境和未来前景的评论 - 公司对lacutamab在T细胞淋巴瘤适应症的潜力保持乐观,并将与FDA讨论加速审批的可能性 [66][67] - 公司对ANKET和ADC管线的发展前景充满信心,认为这些创新技术平台将为公司带来长期价值 [32][33][43] - 公司有充足的现金储备,有望为未来2年的运营提供资金支持 [95] 问答环节重要的提问和回答 问题1 **Rabib Chaudhury 提问** 对于SAR443579的剂量情况,以及对ANKET平台的启示 [57] **Yannis Morel 回答** SAR443579在1mg/kg剂量水平显示了最佳疗效,这可能反映了多特异性药物在不同靶点之间存在剂量优化的需求。这种现象在其他多特异性药物中也有所体现,公司会根据具体靶点特点来优化ANKET分子的剂量 [59][60] 问题2 **Carly Kenselaar 提问** lacutamab在CTCL适应症的未来发展计划 [65] **Mondher Mahjoubi 回答** 公司计划通过合作伙伴推进lacutamab在CTCL的后续临床开发和商业化,并将与FDA讨论加速审批的可能性。同时也会评估在外周T细胞淋巴瘤中的潜力,包括单药和联合用药的临床试验 [66][67][88][89] 问题3 **Arthur He 提问** 对于SAR443579在ASH会议上报告的安全性数据,尤其是4级中性粒细胞减少的情况 [75] **Mondher Mahjoubi 回答** 根据目前公开的摘要信息,SAR443579总体安全性状况良好,但4级中性粒细胞减少的具体原因还需要在ASH会议上进一步解释,是否与疾病进展相关还是药物相关 [76][77]

Company Participants Ashiq Mubarack - Citi Jingming Chen - Evercore ISI Daina Graybosch - Leerink Partners I'd now like to welcome Henry Wheeler to begin the conference. Henry, over to you. On Slide 2, before we start, I'd like to remind you that we will make forward-looking statements regarding the financial outlook in addition to regulatory and product plan development. These statements are subject to risks and uncertainties that may cause actual results to differ from those forecasted. Mondher Mahjoubi I ...

The following interim condensed consolidated financial statements have been approved by the Executive Board of the Company on September 13, 2023, and have been subject to a limited review by our Statutory Auditors. They have been examined by the Supervisory Board of the Company on September 13, 2023. INNATE PHARMA SA HALF-YEAR FINANCIAL REPORT JUNE 30, 2023 INNATE PHARMA S.A. French société anonyme governed by an Executive Board and a Supervisory Board with a share capital of 4,026,535.85 euros composed of ...

Disclaimer on Forward-Looking Information and Risk Factors This document contains forward-looking statements. The use of certain words, including "believe," "potential," "expect" and "will" and similar expressions, is intended to i statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to various risks and uncertairi cause the Company's actual results or financial condition to differ materially from those anticipated. Thes ...

Company Participants Ashiq Mubarack - Citigroup Daina Graybosch - SVB Securities Swayampakula Ramakanth - H.C. Wainwright & Co. Justine Telliez - Kepler Cheuvreux Jingming Chen - Evercore ISI Thank you. Good morning, good afternoon, and welcome, everyone. This morning, Innate issued a press release providing a business update for Q1 2023. We look forward to highlighting the progress made during the year todate as well as addressing future goals and milestones. The press release and today's presentation are ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ OR ☐ SHELL COMPANY REPORT PURSUANT TO SE ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Date of report: For the month of April 2023 Commission File Number: 001-39084 Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F [ X ] Form 40-F [ ] Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Re ...

Europe Demonstrates better anti-tumor efficacy than approved benchmark antibodies in preclinical tumor models. | --- | --- | --- | --- | --- | --- | --- | --- | |------------------|----------------------|--------|-----------------------------------|----------------|-------|-----------------------|----------------| | | | | | | | | | | | IPH6101/SAR'579 | | IPH6401/SAR'514 | IPH62 | | OPTION | | | Ongoing programs | CD123 Phase 1 in AML | | Progression towards IND | B7-H3 Research | | 2 undisclosed targets | ...

Innate Pharma S.A. (NASDAQ:IPHA) Q4 2022 Earnings Conference Call March 23, 2023 9:00 AM ET Company Participants Henry Wheeler - Head, Investor Relations Mondher Mahjoubi - Chief Executive Officer Joyson Karakunnel - Executive Vice President and Chief Medical Officer Yannis Morel - Executive Vice President-Business Development and Product Portfolio Strategy Frederic Lombard - Senior Vice President, Chief Financial Officer Conference Call Participants Carly Kenselaar - Citigroup Daina Graybosch - SVB Securit ...

Exhibit 99.1 Innate Pharma Reports Full Year 2022(1) Financial Results and Business Update MARSEILLE, France--(BUSINESS WIRE)--March 23, 2023--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ("Innate" or the "Company") today reported its consolidated financial results1 for the year ending December 31, 2022. The consolidated financial statements are attached to this press release. "In 2022 we made important progress in our pipeline, both on our clinical and preclinical projects as well as maintaining a ...